306 related articles for article (PubMed ID: 32415340)
1. Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors.
Kasteel EEJ; Darney K; Kramer NI; Dorne JLCM; Lautz LS
Arch Toxicol; 2020 Aug; 94(8):2637-2661. PubMed ID: 32415340
[TBL] [Abstract][Full Text] [Related]
2. Direct comparison of UDP-glucuronosyltransferase and cytochrome P450 activities in human liver microsomes, plated and suspended primary human hepatocytes from five liver donors.
den Braver-Sewradj SP; den Braver MW; Baze A; Decorde J; Fonsi M; Bachellier P; Vermeulen NPE; Commandeur JNM; Richert L; Vos JC
Eur J Pharm Sci; 2017 Nov; 109():96-110. PubMed ID: 28778465
[TBL] [Abstract][Full Text] [Related]
3. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.
Court MH
Methods Enzymol; 2005; 400():104-16. PubMed ID: 16399346
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers.
Izukawa T; Nakajima M; Fujiwara R; Yamanaka H; Fukami T; Takamiya M; Aoki Y; Ikushiro S; Sakaki T; Yokoi T
Drug Metab Dispos; 2009 Aug; 37(8):1759-68. PubMed ID: 19439486
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes.
Badée J; Qiu N; Collier AC; Takahashi RH; Forrest WF; Parrott N; Schmidt S; Fowler S
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S42-S55. PubMed ID: 31502688
[TBL] [Abstract][Full Text] [Related]
6. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
[TBL] [Abstract][Full Text] [Related]
7. Glucuronidation in humans. Pharmacogenetic and developmental aspects.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Jun; 36(6):439-52. PubMed ID: 10427468
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte nuclear factor 1 alpha and 4 alpha are factors involved in interindividual variability in the expression of UGT1A6 and UGT1A9 but not UGT1A1, UGT1A3 and UGT1A4 mRNA in human livers.
Aueviriyavit S; Furihata T; Morimoto K; Kobayashi K; Chiba K
Drug Metab Pharmacokinet; 2007 Oct; 22(5):391-8. PubMed ID: 17965524
[TBL] [Abstract][Full Text] [Related]
9. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms.
Court MH; Duan SX; von Moltke LL; Greenblatt DJ; Patten CJ; Miners JO; Mackenzie PI
J Pharmacol Exp Ther; 2001 Dec; 299(3):998-1006. PubMed ID: 11714888
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.
Innocenti F; Iyer L; Ramírez J; Green MD; Ratain MJ
Drug Metab Dispos; 2001 May; 29(5):686-92. PubMed ID: 11302935
[TBL] [Abstract][Full Text] [Related]
11. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors.
Walsky RL; Bauman JN; Bourcier K; Giddens G; Lapham K; Negahban A; Ryder TF; Obach RS; Hyland R; Goosen TC
Drug Metab Dispos; 2012 May; 40(5):1051-65. PubMed ID: 22357286
[TBL] [Abstract][Full Text] [Related]
12. In vitro assay of six UDP-glucuronosyltransferase isoforms in human liver microsomes, using cocktails of probe substrates and liquid chromatography-tandem mass spectrometry.
Seo KA; Kim HJ; Jeong ES; Abdalla N; Choi CS; Kim DH; Shin JG
Drug Metab Dispos; 2014 Nov; 42(11):1803-10. PubMed ID: 25122565
[TBL] [Abstract][Full Text] [Related]
13. Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver.
Liu W; Ramírez J; Gamazon ER; Mirkov S; Chen P; Wu K; Sun C; Cox NJ; Cook E; Das S; Ratain MJ
Hum Mol Genet; 2014 Oct; 23(20):5558-69. PubMed ID: 24879639
[TBL] [Abstract][Full Text] [Related]
14. Pterostilbene supplements carry the risk of drug interaction via inhibition of UDP-glucuronosyltransferases (UGT) 1A9 enzymes.
Jiang L; Zhang Z; Xia Y; Wang Z; Wang X; Wang S; Wang Z; Liu Y
Toxicol Lett; 2020 Mar; 320():46-51. PubMed ID: 31812603
[TBL] [Abstract][Full Text] [Related]
15. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases.
Ethell BT; Anderson GD; Burchell B
Biochem Pharmacol; 2003 May; 65(9):1441-9. PubMed ID: 12732356
[TBL] [Abstract][Full Text] [Related]
16. UDP-glucuronosyltransferase (UGT) 1A1 mainly contributes to the glucuronidation of trovafloxacin.
Fujiwara R; Sumida K; Kutsuno Y; Sakamoto M; Itoh T
Drug Metab Pharmacokinet; 2015 Feb; 30(1):82-8. PubMed ID: 25760534
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.
Guillemette C; Lévesque É; Rouleau M
Clin Pharmacol Ther; 2014 Sep; 96(3):324-39. PubMed ID: 24922307
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance.
Mackenzie PI; Miners JO; McKinnon RA
Clin Chem Lab Med; 2000 Sep; 38(9):889-92. PubMed ID: 11097345
[TBL] [Abstract][Full Text] [Related]
19. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9.
Court MH; Duan SX; Guillemette C; Journault K; Krishnaswamy S; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2002 Nov; 30(11):1257-65. PubMed ID: 12386133
[TBL] [Abstract][Full Text] [Related]
20. In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug-drug interactions.
Lee SJ; Park JB; Kim D; Bae SH; Chin YW; Oh E; Bae SK
Toxicol Lett; 2015 Jan; 232(2):458-65. PubMed ID: 25448279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
